Módszerek összehasonlítása
Tekintse át a kiválasztott módszereket egymás mellett; az eltérő sorok kiemelve jelennek meg.
| Disease Activity Score 28-Joint (DAS28)× | A Systemicus Lupus Erythematosus Betegségaktivitási Index 2000 (SLEDAI-2K)× | |
|---|---|---|
| Tudományterület | Reumatológia | Reumatológia |
| Módszercsalád | Process / pipeline | Process / pipeline |
| Keletkezés éve≠ | 1995 | 2002 |
| Megalkotó≠ | Prevoo et al. | Gladman et al. |
| Típus | Clinician-rated | Clinician-rated |
| Alapmű≠ | Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48. DOI ↗ | Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291. link ↗ |
| Alternatív nevek | DAS28, DAS28-CRP, DAS28-ESR | SLEDAI, SLEDAI-2K, SLE Disease Activity Index |
| Kapcsolódó | 3 | 3 |
| Összefoglaló≠ | The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden. | The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease. |
| ScholarGateAdatkészlet ↗ |
|
|